Phase 3 Readout
NVS: Phase 3 Topline: A Phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses
November 23, 2026 · vaso-occlusive. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- November 23, 2026
- Company
- Novartis AG (NVS)
- Drug
- vaso-occlusive
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses
- Company
- Novartis AG (NVS)
- Drug
- vaso-occlusive
- Indication
- Sickle Cell Disease (SCD)
Other upcoming events for NVS
Phase 3 ReadoutPhase 3 Topline: PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Cha
Phase 2 StartPhase 2 Start: A Phase IIb Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-range Study to Assess th
Phase 3 ReadoutPhase 3 Topline: A Randomized, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 V
Phase 3 ReadoutPhase 3 Topline: A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase IIIb Study Evalua
Phase 2 StartPhase 2 Start: VEX-AR: Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase 2 Study Evaluating the Efficacy